meta charset="utf-8"> About Us
About Us
Company Overview

Affinity Biopharma is a global, clinical stage biopharmaceutical company focused on advancing innovative technology and first-in-class anti-tumor treatment. We have established our Tumor MicroEnvironment Activated (TMEA) platform technology including TMEA-SMDC, TMEAbody®, TMEAkine®, TMEA-ICE®, ADC and TMEA-XDC platforms, which allow selective unleash of the active drug in the tumor microenvironment, solving “on target/ off tumor toxicity”, enhancing efficacy at targeted sites and dramatically improving the therapeutic index.

Affinity Biopharma has built the tumor microenvironment activated, intelligent platform for small molecule drugs and biologics. TMEA-SMDC (Small Molecule Drug Conjugate) platform transforms the traditional chemotherapy, target therapy and immune agonists into first-in-class, precision guided TMEA cancer therapy, which could replace the original drug and is suitable to combine with immunotherapy. Affinity Biopharma’s biologics platform (including TMEAbody®, TMEAkine®, TMEA-ICE®, ADC and TMEA-XDC) conjugates cytokines, antibodies, immune cell engagers, and fusion proteins to create new generation of innovative drugs with global rights.

Affinity Biopharma was established in December 2011 and headquartered in Shanghai, China. We are a global originator, with 100% original pipeline and innovative drugs with global rights and proprietary protection. Among them, our first TMEA SMDC drug has entered Pivotal (Phase II/III) trial. We aim to address the unmet medical needs, and open up a new era of combination therapy.

Our vision is as follows: “Compassionate and Innovative, Aim for Curative Therapeutic Solution for Cancer Patients”. In the next 10 to 20 years, we look forward to revolutionizing cancer treatment through innovative technology platform, turning malignant tumors into chronic and controllable diseases with long-term survival. To achieve this goal, we would actively carry out various forms of cooperation and innovation with worldwide biopharmaceutical companies and academic research institutions. In the meantime, through licensing and strategic partners, we would be able to broaden our platform application and bring greater values to patients and the whole society.

Management team
The management team of Affinity Biopharma has a global vision and expertise in the fields of Tumor MicroEnvironment Activated (TMEA) technology and drug development, immunology, oncology, protease, business operations, and clinical research and registration.
  • Dr. Cheng Liu is the Founder and CEO of Affinity Biopharma, the originator of the Tumor MicroEnvironment Activated (TMEA) drug platform, and an authoritative scientist in the field of intelligent drug design. Dr. Cheng Liu has a deep understanding and long-term experience in tumor treatment, immunology, and the role and mechanism of protease in the tumor microenvironment.

    Dr. Cheng Liu’s previous experience includes:

    • Prof., Department of Immunology, The Scripps Research Institute
    • Engaged in immuno-oncology research, published more than 30 tumor-related articles and 6 patents in US, and in charge of over ten NIH R01 projects, totaling tens of millions of US dollars in research funds.
    • Postdoc., The Scripps Research Institute 
    • Ph.D., State University of New York
    • M.D., Shanghai Jiao Tong University School of Medicine
    Cheng Liu, M.D., Ph.D.Founder, CEO & Co-CMO
  • Dr. Yuan Liu is the Chief Technology Officer of Affinity Biopharma. Before joining Affinity Biopharma, he conducted postdoctoral research and worked as a researcher at the Scripps Research Institute in the United States. Dr. Yuan Liu has worked in several companies including MabPrex and Fosun Pharma as protein drug development scientist. Dr. Yuan Liu has more than 20 years of experience in protein drug research and development.

    In 2012, the first tumor protease-activated antibody was designed and published (Molecular Pharmaceutics 2012, 9(1), pp 168-175). In 2015, the first tumor protease-activated bispecific antibody was designed and published (Mecular Pharmaceutics 2015 Jul 6; 12(7):2544-50). In 2014, Dr. Yuan Liu was awarded the title of “Shanghai Pujiang Talent”, and in 2015, he was awarded the title of “Zhangjiang Excellent Talent”. In 2018, he was awarded the title of "Shanghai Outstanding Academic/Technical Leader".

    Yuan Liu, Ph.D.Chief Technology Officer
  • M.D. Chris Huang is the Chief Medical Officer of Affinity Biopharma. Before joining Affinity Biopharma, he served as the CMO of Phagelux Global, the CMO of Pharmacons Global, Clinical Development VP of WuXi AppTec, Country Medical Director of AstraZeneca Singapore, Asia Pacific VP of PharmaNet, and Medical Director of Bayer Pharma China. M.D. Chris Huang has 30 years of experience in international clinical development and management of new drugs.

    M.D. Chris Huang graduated from Shanghai Jiao Tong University Medical School, and the School of Pathology at University of New South Wales, Australia.

    Chris Huang, M.D.Co-CMO
Shanghai Affinity Biopharmaceutical Co.,Ltd.


R&D and Business Development Cooperation:

Address: Suite O, 4th Floor,780 Cailun Road, Pudong, Shanghai, P.R. China